Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 4 | BMC Medicine

Fig. 4

From: Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis

Fig. 4

Budget impact analysis of CBD in Iranian health system. This figure compares the healthcare expenditures under two scenarios: scenario 1 (without CBD) and scenario 2 (with CBD) for the years 2024 to 2028. The red bars represent the budget impact attributed to the introduction of CBD, highlighting the financial implications over time as the market share of CBD gradually increases

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us